Key Highlights

  • Clarivate (NYSE:CLVT) completed the sale of its Life Sciences and Healthcare Business on October 6, 2026 for net cash proceeds of USD 488.4 million, against a USD 600 million headline price announced July 6.
  • Third quarter net loss was USD 80.8 million, or USD 0.13 per share, including a USD 62.2 million non-cash Goodwill impairment, against a USD 28.3 million loss a year earlier.
  • Adjusted Net Income rose to USD 136.0 million, or USD 0.21 per diluted share, from USD 119.3 million and USD 0.18, on the company's adjusted basis.
  • Total Debt was USD 4,176.1 million at September 30, 2026, before sale proceeds; published market data showed a price of USD 2.33, up 11.24%, on 2.745 million shares.

Sale Closes and Third Quarter Loss Widens on Impairment

Clarivate (NYSE:CLVT) reported third quarter 2026 results on November 3, 2026, the first to treat its Life Sciences and Healthcare unit as discontinued. The buyer, Investment firm Altaris, agreed on July 6 to pay USD 600 million, made up of USD 500 million at closing, USD 25 million deferred until a transition agreement ends and a USD 75 million seller note. The deal closed October 6 for net cash proceeds of USD 488.4 million, and the company has said it plans to use cash to reduce debt. Continuing-operations Revenue was USD 481.6 million against USD 530.3 million a year earlier. The reported net loss of USD 80.8 million included the USD 62.2 million impairment.

Debt Load and the Arithmetic After the Sale

Total debt stood at USD 4,176.1 million on September 30, 2026, which is before the October proceeds. If all USD 488.4 million went to debt, the balance would be about USD 3.69 billion, a hypothetical built on two published numbers. Against the midpoint of the new continuing-operations adjusted EBITDA outlook of USD 865 million to USD 885 million, that would be roughly 4.2 times, also simple arithmetic. Free Cash Flow was USD 110.2 million in the quarter, and the updated full-year outlook calls for USD 320 million to USD 340 million, with adjusted diluted EPS of USD 0.73 to USD 0.77. The release gave no prior-guidance comparison on the same basis, so a raise or cut cannot be confirmed.

What Penny Stock Status Means for the Move

At USD 2.33, Clarivate (NYSE:CLVT) is a penny stock under the USD 5 threshold used here, and the 11.24% gain on 2.745 million shares comes from published market data whose snapshot date is unconfirmed. In a penny stock a small number of trades can move the price, spreads can be wide, and quoted gains can reverse; nothing here implies the move continues. The nine-month goodwill Impairment of USD 283.9 million shows how much value was written off in the divested unit. Share repurchases totaled USD 18.1 million over nine months. Market Capitalization was not verified, and the adjusted figures exclude items that the GAAP loss includes.

Where Things Stand

Plans point to debt reduction, but the release does not itemize it. Clarivate (NYSE:CLVT) received USD 488.4 million of net cash on October 6, 2026, a few days after its quarter ended, and stated an intention to reduce borrowings, with total debt of USD 4,176.1 million at September 30 as the starting point. The remaining business guides to USD 865 million to USD 885 million of adjusted EBITDA for 2026. The next evidence is the fourth quarter report, plus any disclosed paydown of notes. As a penny stock, the share price can move sharply on small volume.